In a release on
"Our 2013 financial results highlight our progress with ADCETRIS, which now has approvals or marketing authorizations in 39 countries and generated total 2013 global net sales of more than
Recent ADCETRIS Highlights
-Negotiated an agreement with the
-Received orphan drug designation from the
-Reported on data from multiple clinical trials of ADCETRIS, including its evaluation in frontline HL, frontline mature T-cell lymphoma (MTCL), relapsed cutaneous T-cell lymphoma (CTCL) and relapsed DLBCL at the 2013
-Takeda received marketing authorizations for ADCETRIS in
-ADCETRIS was added to the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of relapsed CD30-positive peripheral T-cell lymphoma (PTCL).
ADCETRIS is currently not approved for use in any frontline setting, or for the treatment of relapsed CTCL, DLBCL or PTCL other than sALCL.
ADC Pipeline and Collaborator Updates
-Reported interim phase 1 data from an ongoing trial of SGN- CD19A in acute lymphoblastic leukemia (ALL) at the ASH annual meeting.
-Initiated a phase 1 trial of SGN-LIV1A, an ADC for patients with LIV-1-positive metastatic breast cancer.
-Expanded an ADC collaboration with
-Received milestone payments under an ADC collaboration with
Other Recent Highlights
-Named John A. Orwin to the Board of Directors. Orwin is a biotechnology and pharmaceutical industry veteran with nearly 25 years of experience, including senior leadership positions in many commercial oncology organizations. He currently serves as Chief Executive Officer of
-Promoted Chris Boerner to Executive Vice President, Commercial;
-Named David Fontana, Ph.D., as Vice President, Portfolio and Program Management and ADCETRIS Program Director.
Upcoming 2014 Milestones
-Report ADCETRIS phase 3 AETHERA clinical trial data in the second half of 2014.
-Present data from a phase 1/2 clinical trial of ADCETRIS in combination with bendamustine in second-line HL on
-Present additional clinical data from ADCETRIS, including phase 2 clinical trials in DLBCL and in frontline HL patients age 60 and above.
-Present data from phase 1 trials of SGN-CD19A in non-Hodgkin lymphoma and ALL.
-Present data from a phase 1 trial of SGN-CD33A in acute myeloid leukemia (AML).
-Initiate a phase 1 trial of SGN-CD70A in CD70-positive malignancies in the second half of 2014.
Fourth Quarter and Year 2013 Financial Results
Total revenues in the fourth quarter of 2013 were
Total costs and expenses for the fourth quarter of 2013 were
Under the ADCETRIS collaboration with Takeda, development costs incurred by
Non-cash, share-based compensation cost for the year in 2013 was
Net loss for the fourth quarter of 2013 was
2014 Financial Outlook
Research and development expenses are expected to be in the range of
((Comments on this story may be sent to firstname.lastname@example.org))
In a release on